

2006 Fact Book



Founded in 1888 by Dr. Wallace C. Abbott, a Chicago physician, Abbott is a broad-based health care company that discovers, develops, manufactures and markets products that span the continuum of care — from prevention and diagnosis to treatment and cure. Abbott's principal businesses include pharmaceuticals and medical products, including devices, diagnostic tests, instruments and nutritional products for children and adults.

Headquartered in north suburban Chicago, Abbott serves customers in more than 130 countries, with a staff of 65,000 at more than 100 manufacturing, distribution, research and development, and other locations.

## Contents

2	Financial Highlights
4	Market-Leading Positions and Abbott's Leading Brands
5	Rankings
6	Medical Products
8	Medical Products – Diagnostics
9	Medical Products – Diabetes Care
9	Medical Products – Molecular
10	Medical Products – Point of Care
10	Medical Products – Nutrition
12	Medical Products – Vascular
13	Medical Products – Spine
13	Medical Products – Animal Health
14	Pharmaceutical Products
18	TAP Pharmaceutical Products
19	History
22	Advancing Global Citizenship
26	Five-Year Financial Summary
28	Plant Locations
28	Directors
29	Senior Management and Corporate Vice Presidents


Abbott is focused on advancing patient care by developing innovative solutions in diagnostics, medical devices, nutritional products and pharmaceuticals.

# Financial Highlights


In 2005, Abbott reported sales and income from continuing operations of \$22.3 billion and \$3.4 billion, respectively. Abbott also recorded its 328th consecutive quarterly dividend to be paid to shareholders since 1924. In addition, 2005 marked the 33rd straight year Abbott's dividends have increased. Our medical products business — which includes Diagnostics, Nutritionals, Diabetes Care, Molecular, Point of Care, Vascular, Spine and Animal Health — generated more than \$8 billion in sales. The company's pharmaceutical business — which includes U.S. and international pharmaceuticals — generated sales of more than \$13 billion.

Abbott's leadership positions in several multibillion-dollar businesses provide a unique balance of revenue and growth opportunities and cash flow sources that allow the company to invest in its future. In 2005, to further strengthen its business and sustain its success, Abbott invested more than \$1.8 billion in research and development. During 2005, Abbott's operating cash flow from continuing operations was \$5 billion.

**2005 Sales by Division**  
Total: \$22.3 billion




**Net Sales Worldwide\***  
(dollars in billions)



\*Reflects the April 2004 spinoff of Hospira.

**Cash dividends declared per share**  
(in dollars per share)



# Market-Leading Positions and Abbott's Leading Brands

## Anti-Infectives

*Biaxin/Biaxin XL*  
*Omnicef*  
*Klacid/Klaricid*  
(outside the U.S.)

## Blood Screening

*Abbott Prism* system  
Viral screening reagents

## Carotid Artery Disease

*Acculink/Accunet*  
carotid stent platform  
*Xact/EmboShield*  
carotid stent platform

## Cholesterol/Triglyceride Management

*TriCor*

## Coronary Devices

*Hi-Torque Balance*  
*MiddleWeight* guidewire

## Coronary Stents

*Multi-Link Vision*  
*Multi-Link Mini Vision*

## Glucose Monitoring

*FreeStyle Flash*  
(*FreeStyle Mini* outside the U.S.)  
*Precision Xtra*  
(*Precision Optium/Xceed*  
outside the U.S.)  
*Precision PCx*  
*AlphaTRAK*

## Healthy Living Nutrition

*EAS*  
*Ensure*  
*Glucerna*  
*ZonePerfect*

## Hematology Diagnostics

*Cell-Dyn* system  
and reagents

## Immunodiagnostics

*Architect* system  
and reagents  
*AxSym* system  
and reagents

## Immunology

*Humira*

## Inhalation Anesthetics

*Ultane/Sevorane*  
*SevoFlo*

## Neurological Treatments

*Depakote ER/Depakote*

## Pediatric Nutrition

*Similac Advance*  
*Alimentum Advance*  
*Isomil Advance*  
*PediaSure*

## Point of Care

*i-STAT* system  
and reagents

## Protease Inhibitors for HIV/AIDS

*Kaletra*  
*Norvir*

## Renal Care

*Zemplar*

## Thyroid Hormone Replacement

*Synthroid*

## Vessel Closure Devices

*StarClose*  
*Perclose* products

# Rankings

Abbott is ranked among the top companies in the world for financial strength and workplace excellence by leading national publications, including:

---

**Fortune** Ranked 5th among the "Most Admired Companies" in the pharmaceutical sector.

Ranked 93rd on the *Fortune 500* list of the largest U.S.-based corporations (ranked by 2005 revenue).

---

**DiversityInc.** Named in top 10 of "Top 50 Companies for Diversity."

---

**Forbes** Ranked 160th on the *Forbes 2000* list (ranked by sales, profits, assets and market value).

---

**Working Mother** Named one of the "100 Best Employers for Working Mothers."

---

**Science** Listed among the top 20 employers for scientists in a ranking of the world's most respected biotechnology and pharmaceutical companies.

---

**The Scientist** Listed among *The Scientist's* best places to work in industry.

# Medical Products

Abbott has built leading businesses in diagnostic testing and instrumentation, medical devices and nutritional products for children and adults. Abbott is committed to developing innovative, highly differentiated products for patients and consumers.

Diabetes Care  
FreeStyle Flash  
FreeStyle Mini



Molecular  
Real-Time PCR



Diagnostics  
Architect ci8200

Nutrition  
Healthy Living



Vascular  
Emboshield



Spine  
InFix



## Medical Products — Diagnostics

Abbott offers a broad range of innovative instruments and tests across key segments in the global diagnostics market, including hospitals, reference laboratories, blood banks, physicians' offices and clinics. Abbott Diagnostics provides a broad portfolio of products to serve clinical laboratory customers worldwide.

**Immunoassay and Clinical Chemistry.** Includes systems and assays to measure a variety of analytes found in the blood and to diagnose and monitor diseases and therapies. Also includes blood screening instrumentation and assays used to ensure the safety of the blood supply.

**Abbott Prism** Fully automated analyzer specifically designed for high-volume multiple centers and blood banks to screen donated blood for multiple viral assays. Menu includes HIV, hepatitis and HTLV (immune system virus) assays. (Not all assays are available in the United States.)

**AbbottLink** Software that transmits instrument performance information to Abbott's service operations through the Internet, enhancing the remote identification and rapid resolution of technical issues on select analyzers.

**Accelerator Automated Processing System** Automates the labor-intensive, repetitive motion in the laboratory. *Accelerator APS* improves process consistency, reduces dependency on manual labor and enhances overall operator safety.

**Accelerator Decision Manager** Software that provides connectivity and functionality across the entire laboratory, reducing turnaround time and labor dependency, while improving the quality of results.

**Aeroset and Architect c8000** High- and medium-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty testing.

**Architect i2000, i2000<sub>SR</sub>** Modular analyzers that provide immunoassay testing. Menu includes tests for cancer, cardiovascular and thyroid disease, fertility, infectious diseases and pregnancy.

**Architect ci8200** Analyzer that integrates the c8000 and i2000<sub>SR</sub> to provide a consolidated workstation to perform both clinical chemistry and immunoassay tests.

**AxSym** Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular and thyroid disease, drugs of abuse, fertility, hepatitis and pregnancy.

**IMx** Automated benchtop analyzer for immunoassay testing. Menu includes tests for thyroid and cardiovascular disease, cancer and fertility.

**TDx and TDx Flix** Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline, vancomycin, drugs of abuse and thyroid tests.

**OraQuick Advance** Rapid, simple test for HIV type 1 and type 2. (Marketed in the United States under a distribution agreement with OraSure Technologies, Inc.)

**Hematology.** Abbott develops, manufactures and markets *Cell-Dyn* hematology systems used to perform sophisticated blood cell analysis.

**Cell-Dyn Sapphire** A high-volume, automated hematology analyzer that incorporates monoclonal antibody tests, reducing the need for external sample analysis.

**Cell-Dyn 4000, 3700, 3200, 1800, 1700** A complete line of highly automated hematology analyzers to meet the testing needs of any laboratory, whether high or low volume.

## Medical Products — Diabetes Care

Abbott Diabetes Care is committed to improving the lives of people with diabetes by providing innovative glucose monitoring systems that offer patients and health care professionals fast, convenient and accurate results.

**FreeStyle Flash (FreeStyle Mini outside the United States)** The world's smallest blood glucose meter, offering virtually pain-free testing and innovative features, including a backlit display, four daily programmable alarms to remind patients to test, a 0.3 microliter blood sample and a 7-second average testing time.

**FreeStyle Freedom** An easy-to-hold, easy-to-read blood glucose meter which uses the world's smallest blood sample (0.3 microliter), has the most approved alternate-site testing and delivers a fast 5-second average testing time.

**Precision Xtra (Precision Optium/Xceed outside the United States)** The only home-use meter capable of measuring both blood glucose and blood ketone levels.

**Precision PCx** A hand-held, point-of-care blood glucose testing system developed to meet the unique testing and data management needs of the hospital that offers improved data communication speeds and an end-fill strip technology.

**Precision Link** A free Web-based data management system for people with diabetes, compatible with both *Precision* and *FreeStyle* blood glucose meters.

## Medical Products — Molecular

Abbott Molecular provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. Includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA.

**Abbott Real-Time tests for HIV-1, HCV and CT/NG** Molecular tests for use on the m2000 automated system, based on real-time PCR (polymerase chain reaction) technology. The tests are used to monitor hepatitis C and HIV-1 viral loads and to diagnose chlamydia and gonorrhea infections. (Available outside the United States.)

**Abbott m2000** This system integrates sample preparation with real-time PCR amplification and detection technology to provide full automation, from sample extraction to the reporting of final patient results.

**m1000** An automated, stand-alone instrument used to purify and extract RNA and DNA from patient samples using novel magnetic particle technology.

**PathVysion HER-2 DNA Probe Kit** Detects the HER-2 gene in breast cancer patients. Patients who have extra copies of this gene are candidates for treatment with Herceptin, a targeted monoclonal treatment.

**UroVysion** A DNA-based test for the initial diagnosis of patients with bladder cancer presenting with hematuria (blood in urine), suspected of having bladder cancer and the monitoring of bladder cancer recurrence. Detects genetic changes in bladder cells.

**ViroSeq HIV-1** Genotyping system used by physicians as an aid in monitoring and treating HIV infection. Designed to detect mutations in the HIV-1 virus that are associated with drug resistance. (Marketed by Abbott as part of its alliance with Celera Diagnostics.)

## Medical Products — Point of Care

Abbott Point of Care develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis.

---

<i>i-STAT</i>	A market-leading, hand-held blood analyzer that delivers results in a few minutes at the patient's bedside utilizing single-use, disposable cartridges that include panels of tests for electrolytes, metabolites, blood gases, coagulation and cardiac markers.
---------------	--

---

## Medical Products — Nutrition

Abbott is a leader in providing trusted pediatric and healthy living nutritional products and related health care products to improve people's quality of life. Ross Products develops and markets nutritional products for the United States, while Abbott Nutrition International markets nutritional products outside the United States.

---

**Pediatric Nutrition.** Abbott develops products that support the growth and development of infants and children and makes these products available in innovative, consumer-friendly packaging. Specialty formulations include products for premature and low-birth-weight infants and products for infants and children with special tolerance or nutritional needs.

---

<i>Alimentum Advance</i>	Formula for infants with food allergies or colic due to protein sensitivity.
<i>Formance/Mama's Best/Similac Mom</i>	Maternal supplement scientifically designed for pregnant and breastfeeding mothers to provide increased daily nutrition.
<i>Gain Advance</i>	A nutritional supplement for children 6 months to 1 year old during the transition to solid foods. <i>Gain Advance</i> is also available with the enhanced mental and visual nutrients of the <i>Eye-Q</i> system.
<i>Gain Plus Advance</i>	Nutritional choice for children 1 year to 3 years old. The <i>Eye-Q</i> system is also available with <i>Gain Plus Advance</i> .
<i>Grow Advance</i>	Growth-focused nutritional supplements for children 3 years old and beyond, delivering more than 30 essential nutrients. <i>Grow Advance</i> is also available with the <i>Eye-Q</i> system of nutrients.
<i>Isomil</i>	A broad line of soy-based formulas for infants and toddlers with common feeding problems such as fussiness, gassiness and spitting-up.
<i>Pedialyte</i>	Oral electrolyte maintenance solution to help prevent dehydration by quickly replacing fluids and electrolytes lost during diarrhea and vomiting. Also available as <i>Pedialyte Freezer Pops</i> and <i>Pedialyte Singles</i> .
<i>PediaSure</i>	Complete, balanced nutritional formula in a variety of flavors for children ages 1 to 10 years. Available with fiber, as an oral supplement and in a tube-feeding formulation.
<i>Similac</i>	A complete line of infant and toddler formulas that offer DHA, RHA and a patented blend of nucleotides to help support healthy development of the baby's eyes, brain and immune system. The line also includes highly specialized products to meet the unique needs of premature and low-birth-weight babies, including <i>Similac Human Milk Fortifier</i> , <i>Similac SpecialCare</i> and <i>Similac NeoSure</i> .

---

---

**Healthy Living.** Abbott offers a broad selection of nutrition bars, shakes and related products that satisfy a wide range of consumer nutrition needs.

---

<i>EAS</i>	A leading brand of nutrition bars, shakes and supplements designed to help active-lifestyle consumers meet their fitness, performance and endurance goals.
<i>Ensure, Ensure Healthy Mom</i>	A broad line of leading adult nutritional products, providing a source of complete, balanced nutrition to help consumers stay active, healthy and energetic. <i>Ensure</i> shakes are available in a variety of flavors and nutritional formulations. <i>Ensure Healthy Mom</i> is designed to help meet the unique nutritional needs of pregnant women and nursing mothers.
<i>Glucerna, Glucerna SR</i>	The first therapeutic nutritional product for people with diabetes or patients experiencing abnormal glucose tolerance. Available in shakes, meal bars, snack bars and tube-feeding formulations. <i>Glucerna SR</i> (marketed outside the United States) is an advanced formulation to improve glycemic control and help people with diabetes achieve or maintain optimal weight management.
<i>ZonePerfect</i>	A leading brand of convenient, portable nutrition bars and shakes designed to satisfy hunger through a unique balance of carbohydrates, protein and fat.
<hr/> <b>Health Care Professional Products.</b> Abbott offers medical nutritionals for patients with special dietary needs who require tube feeding or other nutritional interventions due to complex illness or injury. Abbott also offers specialized nutrition products for infants and children with multiple food allergies, severe gastrointestinal impairment or metabolic diseases.	
<i>Companion, Embrace, Flexiflo, Patrol and Quantum</i>	Complete line of enteral feeding pumps, tubes and devices.
<i>EleCare</i>	Nutritional formula for infants and children with multiple food allergies or severe gastrointestinal impairment.
<i>Jevity</i>	Fiber-fortified, high-protein liquid formula for both short- and long-term tube feeding.
<i>Oxepa and Pulmocare</i>	Specialized nutritional products for patients with respiratory conditions, including acute lung injury ( <i>Oxepa</i> ) and pulmonary disease ( <i>Pulmocare</i> ).
<i>ProSure</i>	A therapeutic, clinically proven nutritional product, specially designed to help people with cancer-induced weight loss to gain weight, strength and improve their quality of life. (Marketed outside the United States.)

---

## Medical Products — Vascular

Abbott Vascular markets a broad portfolio of coronary, endovascular and vessel closure technologies used in the treatment of vascular disease.

### Coronary

<i>Asahi guidewires</i>	A full product line of guidewires that facilitate access to diseased vessels and allow the clinician to thread interventional devices to the most difficult-to-reach areas of the vasculature in angioplasty procedures.
<i>Hi-Torque guidewires</i>	A full line of coronary guidewires to assist the interventional cardiologist in accessing treatment area.
<i>Mercury and Voyager balloons</i>	A line of coronary balloons enabling the potential for optimal stent expansion in the arteries surrounding the heart.
<i>Multi-Link Vision, Multi-Link Mini Vision stent</i>	Thin-strut metallic stent based on cobalt chromium technology for coronary obstructions from 2.0 to 4.0 mm.
<i>TriMaxx</i>	A bare metal coronary stent with extremely thin struts (mesh scaffolding) and an ultralow crossing profile designed to ease stent placement in arteries surrounding the heart. (Approved outside the United States.)
<i>Xience V stent system</i>	A next-generation drug-eluting coronary stent system developed on the <i>Multi-Link Vision</i> platform. The <i>Xience V</i> stent system combines the cobalt chromium stent with everolimus, to treat coronary obstructions and prevent post-procedure vessel renarrowing. (Approved outside the United States.)

### Endovascular

<i>Absolute, Dynalink</i>	Biliary self-expanding stent systems used to treat obstructions in the bile duct.
<i>Acculink, Accunet</i>	The first carotid stent system to launch in the United States, the <i>Acculink</i> carotid stent is an easy to use, accurate and conformable self-expanding nitinol stent available on a rapid exchange delivery system. Used with the <i>Accunet</i> system, a filter with a nitinol basket to capture plaque fragments (emboli) that may be dislodged during the carotid stenting procedure.
<i>Herculink Elite, Omnilink</i>	Peripheral biliary balloon expandable stent systems used to treat obstructions in the bile duct.
<i>Xact, Emboshield</i>	<i>Xact</i> is a self-expanding stent designed specifically for use in the carotid arteries of the neck that carry blood to the brain. <i>Emboshield</i> is a filter used to capture emboli that may be dislodged during carotid stenting procedures.
<i>Xceed, Xpert</i>	Biliary self-expanding stent systems designed to treat bile duct obstructions.

### Vessel Closure

<i>Closer S, Perclose A-T, Perclose ProStar</i>	Suture-mediated vessel closure devices designed to expedite recovery following catheterization procedures.
<i>StarClose</i>	Vascular closure device that features a flexible nitinol clip to enable secure extravascular closure of the femoral artery access site in diagnostic catheterization procedures.

## Medical Products — Spine

Abbott Spine, an innovative leader in spinal implant technology, offers surgeons a unique product line with technologically advanced devices for neck and back surgery. In addition, Abbott Spine is concentrating on the development of non-fusion technologies that are minimally invasive and do not involve substantial reconstruction of the spine.

### Minimally Invasive Systems

<i>PathFinder</i>	A minimally invasive device used in lower-back surgery requiring only two small incisions, potentially reducing surgical pain and allowing patients to go home sooner.
<i>TraXis</i>	A device placed in the spine with unique instruments for implantation to restore strength and stability to the mid and lower spine.

### Thoracolumbar Systems

<i>InCompass</i>	An implant system designed for the mid and lower back to promote stability and fusion of the vertebrae.
<i>BacFix</i>	A device implanted in the mid to lower back to promote spinal fusion.

### Cervical and Cervicothoracic Systems

<i>SC-AcuFix</i>	A comprehensive line of implants and instrumentation that provide stabilization of the neck during the development of spinal fusion.
<i>Nex-Link</i>	An implant system used in the back of the neck to stabilize the neck and higher segments of the spine.

### Interbody Spacer Systems

<i>InFix</i>	A modular device assembled within the vertebral space to restore a patient's anatomy and provide biomechanical integrity to the spine.
<i>Cadence, Coda, Fortitude</i>	Spacers which are implanted between two vertebral bodies in the mid to lower back to restore biomechanical integrity to the spine.

### Emerging Technologies

<i>Wallis System</i>	A device implanted in the back that potentially allows a patient's spine to continue to move more like a normal spine. (Marketed outside the United States.)
----------------------	--

## Medical Products — Animal Health

Abbott Animal Health is a leader in perioperative health care for the veterinary market. Products include anesthetic and wound care products, nutritionals, a complete line of IV fluid therapy and other veterinary critical care products.

<i>AlphaTRAK</i>	A blood glucose monitoring system specifically calibrated and validated for dogs and cats that provides veterinarians with fast, inexpensive, convenient and accurate blood glucose results.
<i>PropoFlo (propofol)</i>	A versatile intravenous anesthetic characterized by rapid and smooth inductions and recoveries.
<i>SevoFlo (sevoflurane)</i>	An inhalant anesthetic that provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.
<i>Nexaband S/C Adhesive</i>	A medical-grade tissue adhesive that can be used instead of sutures and staples to close incisions. It provides a strong, flexible barrier during healing and eases away naturally within seven to 10 days.



# Pharmaceutical Products

Abbott's premier global pharmaceutical business is dedicated to discovering, developing and marketing breakthrough drugs that improve patient health. In pharmaceutical products, Abbott's primary focus is on translating innovative science into effective medicine to address unmet medical needs.



Renal Care  
Zemplar



Immunology  
Humira



Virology  
Kaletra



Anti-Infectives  
Omnicef

Cardiovascular  
TriCor



Metabolics  
Synthroid



Neuroscience  
Depakote ER

## Pharmaceutical Products

Abbott is dedicated to discovering, developing and marketing breakthrough drugs that improve patient health. Abbott sells pharmaceutical products in several therapeutic areas.

**Anesthesia.** Provides injectable inhalation anesthetic agents, neuromuscular blockers, sedatives and other analgesic pain therapies.

*Mivacron* (mivacurium Cl),  
*Nimbex* (cisatracurium besylate),  
*Nuromax* (doxacurium Cl),  
*Tracrium* (atracurium besylate)

Neuromuscular blockers used as adjuncts to general anesthesia. These products can be used prior to surgery to facilitate nonemergent endotracheal intubation and during surgery or in ICU to facilitate skeletal muscle relaxation and mechanical ventilation.

*Ultane, Sevorane* (sevoflurane)

Inhalation anesthetic for both inpatient and outpatient procedures, for adult and pediatric use.

**Anti-Infectives.** Antibiotics for the treatment of respiratory infections and skin infections.

*Biaxin, Klacid, Klaricid* (clarithromycin),  
*Biaxin XL, Klaricid OD* (extended-release formulation)

Oral macrolide antibiotic for the treatment of upper and lower respiratory tract infections. Clarithromycin is also used for skin and skin structure infections, treatment and prevention of *Mycobacterium avium* complex (MAC) and eradication of the ulcer-causing bacterium *H. pylori*.

Erythromycin, PCE

Generic and polymer-coated macrolide antibiotic.

*Omnicef* (cefdinir)

An oral cephalosporin antibiotic for the treatment of upper and lower respiratory tract infections, including ear infections, sinus infections, throat and tonsil infections, skin infections, bronchitis and pneumonia.

**Cardiovascular.** Includes anti-hypertensive medicines for reducing high blood pressure, treatment for congestive heart failure and medicine for reducing high cholesterol and triglycerides.

*Blipress, Tiadyl* (candesartan)

Angiotensin-2 antagonist for hypertension.

*Mavik* (trandolapril), *Tarka* (trandolapril/verapamil)

Long-acting angiotensin-converting enzyme (ACE) inhibitor and combination of ACE inhibitor and calcium channel blocker, respectively.

*Simdax* (levosimendan)

Injectable for acute congestive heart failure. (Marketed outside the United States.)

*TriCor* (fenofibrate)

Used along with dietary fat restriction to reduce triglycerides and LDL, or "bad," cholesterol and to increase HDL, or "good," cholesterol.

**Gastrointestinal.** Drugs to treat diseases of the GI tract.

*Prevacid, Ogestro* (lansoprazole)

Proton pump inhibitor for gastroesophageal reflux disease (GERD), ulcers and other stomach acid-related disorders. (Marketed in the United States by TAP Pharmaceutical Products Inc.)

**Immunology.** Drugs used to treat diseases of the immune system, including rheumatoid arthritis and psoriatic arthritis.

*Humira* (adalimumab)

Self-injectable, fully human, monoclonal TNF-blocking treatment for rheumatoid arthritis and psoriatic arthritis.

**Metabolics.** Includes medicines for the management of obesity and the treatment of thyroid disease.

*Meridia, Reductil* (sibutramine hydrochloride monohydrate)

Serotonin and norepinephrine re-uptake inhibitor (SNRI) used with a reduced-calorie diet for the management of obesity.

*Synthroid* (levothyroxine sodium)

Synthetic thyroid hormone for the treatment of hypothyroidism and subclinical hypothyroidism.

**Neuroscience and Pain Care.** Drugs to treat neurological conditions, as well as medications for pain management.

*Depakote ER* (divalproex sodium, extended-release tablets)  
*Depakote, Epival, Valcote* (divalproex sodium, enteric-coated tablets)

Anti-epileptic agent (adult/pediatric) also used for the treatment of manic episodes of bipolar disorder and for the prevention of migraine headaches (adult).

*Dilaudid* (hydromorphone hydrochloride)

Analgesic for moderate to severe pain.

*Vicodin* (hydrocodone/acetaminophen)

Analgesic for moderate to moderately severe pain.

*Vicoprofen* (hydrocodone/ibuprofen)

Analgesic for acute pain.

**Pediatric and Neonatal.** Drugs for newborns with serious respiratory conditions.

*Survanta* (beractant)

Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

*Synagis* (palivizumab)

Monoclonal antibody for the prevention of serious respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV.

**Renal Care.** Includes oral and injectable activated vitamin D agents developed to treat patients with complications of chronic kidney disease.

*Zemplar* (paricalcitol injection and capsules)

Next-generation therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.

**Urology and Reproductive Health.** Includes medicines for benign prostatic hyperplasia (BPH), advanced prostate cancer, endometriosis, anemia associated with uterine fibroids and central precocious puberty.

*Hytrin* (terazosin HCl)

Once-a-day alpha blocker for hypertension and symptoms of BPH.

*Lupron Depot, Lucrin* (leuprolide acetate for depot suspension)

Synthetic hormone for the treatment of advanced prostate cancer, endometriosis, preoperative treatment of anemia associated with uterine fibroid tumors in combination with iron, and central precocious puberty. (Marketed in the United States by TAP Pharmaceutical Products Inc.)

**Virology.** Drugs to treat HIV/AIDS.

*Kaletra* (lopinavir/ritonavir)

Advanced-generation protease inhibitor for the treatment of HIV/AIDS (in combination with other antiretroviral agents).

*Norvir* (ritonavir)

Protease inhibitor for the treatment of HIV/AIDS (generally used in combination with other antiretroviral agents).

TAP Pharmaceutical Products Inc., established in 1977, is a joint venture between two global pharmaceutical leaders, Abbott and Takeda Pharmaceutical Company Limited of Japan. TAP is one of the leading pharmaceutical companies in the United States. TAP is unique in that it does not have its own internal discovery or manufacturing organizations. Instead, the company partners with outside organizations and applies its expertise in research and development, quality assurance, and sales and marketing to develop and commercialize new compounds.

TAP focuses its drug development in four major areas: gastroenterology, metabolic disorders, urology and women's health. The company develops and markets pharmaceuticals for sale in the United States and Canada, and licenses international rights for some of these products to Abbott International.

TAP's current products include *Prevacid* (lansoprazole), a proton pump inhibitor for gastroesophageal reflux disease (GERD), ulcers and other acid-related disorders and *Lupron* (leuprolide acetate) for the treatment of advanced prostate cancer, endometriosis, anemia associated with uterine fibroid tumors in combination with iron, and central precocious puberty.

### A tradition of innovation.

For more than a century, Abbott has been a pioneer in developing innovative solutions that improve health and the practice of health care. In 1888, 30-year-old Wallace C. Abbott, M.D., began making a new form of medicine. Using the active — or alkaloid — part of a medicinal plant, he formed tiny pills, called “dosimetric granules,” which provided a measured amount of the drug. The demand for these accurate granules soon far exceeded the needs of his own practice. From a small operation based above Dr. Abbott's pharmacy, Abbott has evolved into one of the world's leading health care companies.

1888	Dr. Abbott begins producing dosimetric granules in his apartment on Chicago's North Side.
1900	The business is officially incorporated in Illinois as the Abbott Alkaloidal Company.
1915	The company changes its name to Abbott Laboratories.
1920	Dr. Abbott breaks ground for a new manufacturing facility in North Chicago, Ill.
1929	Abbott stock is listed on the Chicago Stock Exchange. The offering is 20,000 shares for \$32 each.
1931	Abbott establishes its first international affiliate in Montreal, Canada. The company's international presence will grow steadily.
1936	Abbott introduces the anesthetic agent Pentothal, developed by Abbott scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they are named to the U.S. Inventors Hall of Fame in 1986.
1941	Abbott is one of the five pioneers in the United States to start commercial production of penicillin.
1952	<i>Erythrocin</i> , a new antibiotic with good activity against gram-positive bacteria, is introduced.
1962	Abbott enters into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals. Major plant expansions are completed in England, Italy and France.
1964	The company acquires M&R Dietetic Laboratories, of Columbus, Ohio, which eventually becomes Abbott's Ross Products division.
1965	Abbott moves major operations to Abbott Park, a 420-acre site southwest of its North Chicago headquarters.

1973 Abbott forms its Diagnostics division to bring together all diagnostic products and services. The company also introduces *Ensure*, the first adult medical nutritional.

1977 TAP Pharmaceuticals, now known as TAP Pharmaceutical Products Inc., is formed as a joint venture between Abbott and Takeda Chemical Industries, Ltd., of Japan.

1983 *Depakote*, a new treatment for epilepsy, is approved in the United States.

1985 Abbott wins U.S. approval to market the world's first diagnostic test for AIDS. TAP receives approval for *Lupron*, a new therapy for prostate cancer.

1987 *Hytrin* (terazosin), a new cardiovascular drug for the treatment of hypertension, receives FDA approval.

1988 Abbott celebrates its centennial. The *IMx* immunoassay system is introduced and goes on to become one of the best-selling new products in Abbott's history.

1990 *Biaxin*, an important new macrolide antibiotic, is introduced.

1991 Several major products are introduced worldwide, including *Survanta*, for the treatment of neonatal respiratory distress syndrome. Abbott enters the hematology testing market with the acquisition of Sequoia-Turner Corp.

1993 *Hytrin* receives FDA clearance for use in treating symptoms of benign prostatic hyperplasia, a condition of the prostate. Abbott launches *AxSym*, a new, labor-saving diagnostic system.

1994 Abbott introduces sevoflurane, the first truly universal anesthetic, and completes an agreement to cross-license LCR and PCR, two gene amplification technologies.

1995 TAP receives approval for *Prevacid*, a proton pump inhibitor used in treating ulcers. *Abbott Prism*, the first fully automated, high-volume blood analyzer, is introduced outside the United States.

1996 The company receives FDA approval for *Norvir*, a protease inhibitor for the treatment of HIV and AIDS. The company enters the glucose testing market with its acquisition of MediSense, Inc.

1997 Abbott acquires the parenteral products business of Sanofi Pharmaceuticals, Inc. (later spun off to Hospira), and also launches several new products, including an improved version of *Similac* infant formula in the United States.

1998 Abbott launches *Glucerna* shakes and snack bars, specially formulated nutritionals for people with diabetes. *Depakote* surpasses lithium as the most-prescribed drug for treating mania. Abbott launches several pharmaceutical products, including *Zemplar*, *TriCor* and *Synagis*.

1999 Abbott launches *Architect*, a next-generation diagnostic system, and acquires Perclose, Inc., a leading vascular closure devices company.

2000 Abbott receives FDA approval for several new drugs or line extensions, including *Kaletra* (an advanced-generation protease inhibitor for the treatment of HIV/AIDS), *Biaxin XL* (a once-daily version of its flagship antibiotic), and *Depakote ER* (for migraine prevention).

2001 Abbott completes the acquisition of the pharmaceutical business of BASF, including the global operations of Knoll Pharmaceuticals. In addition, Abbott acquires Vysis, Inc., a leading genomic disease management company.

2002 Abbott receives FDA approval for *Humira* (for rheumatoid arthritis) and *Synthroid* (for hypothyroidism). The company launches *Similac Advance*, *Isomil Advance* and *NeoSure Advance* infant formulas in the United States. Abbott acquires the cardiovascular stent business of Biocompatibles International plc.

2003 Abbott launches three new immunodiagnostic systems on the *Architect* platform. Abbott receives European regulatory approval for *Humira*. Abbott acquires JOMED's coronary and peripheral intervention assets, Spinal Concepts Inc., ZonePerfect Nutritional Co. and Integrated Vascular Systems Inc.

2004 Abbott acquires TheraSense Inc., a leading blood glucose monitoring business, as well as i-STAT Corp., EAS Inc. and Spine Next S.A. Abbott creates Hospira, an independent, publicly traded company. Hospira is one of the largest global specialty pharmaceutical and medication delivery companies serving the hospital.

2005 Abbott introduces several medical devices, including the *Xact/Emboshield* carotid stent system, *StarClose* vascular closure device and, in the United States, diagnostic devices *Abbott Prism* and *Cell-Dyn Sapphire*. Abbott also received FDA approval for two new indications for *Humira* (psoriatic arthritis and early rheumatoid arthritis).

2006 Abbott acquires the vascular business of Guidant Inc., a leader in coronary and vascular products.

## Advancing Global Citizenship

At Abbott, we believe that our right to do business entails a responsibility to society. We recognize that the sustainability of our company depends upon our ability to think and act for the long term for all the people we serve — most importantly, the patients who benefit from our medicines and technologies. From ethics and compliance and diversity and inclusion, to product quality and environment and health and safety, our commitment to good corporate citizenship is an integral part of who we are and how we conduct business.

Through our programs, we engage and partner with many organizations in the pursuit of sustainable solutions to global challenges. For more information on our work, visit [www.abbott.com/citizenship](http://www.abbott.com/citizenship).



# Advancing Global Citizenship

## Improving Access to Medicines

Improving access to affordable medicines is one of the greatest challenges facing the health care industry and our company. We are committed to helping patients access the medicines they need by advancing leading-edge science and technologies, increasing patient awareness about diseases and products, making our medicines available through company- and industry-run programs and participating in public policy dialogue.

### Abbott's Access Programs

#### Abbott Patient Assistance Program

The Abbott Patient Assistance Program is a physician-based referral program that offers free Abbott medicines to low-income patients who do not have or do not qualify for prescription drug benefits through private insurance or government-funded programs. (800) 222-6885 or [www.helpingpatients.org](http://www.helpingpatients.org)

#### Abbott Diabetes Care Patient Assistance Program

The Abbott Diabetes Care Patient Assistance Program offers assistance on blood glucose meters and strips to low-income patients in the United States. [www.abbottdiabetescare.com](http://www.abbottdiabetescare.com)

#### Ross Patient Assistance Program

The Ross Patient Assistance Program offers assistance on metabolic and nutritional products to low-income or uninsured patients in the United States. [www.pparx.org](http://www.pparx.org)

## Industry Initiatives

Abbott participates in a number of industry-wide initiatives to help low-income, uninsured or underinsured patients access free or discounted medicines. We support the Partnership for Prescription Assistance, which brings together America's pharmaceutical companies, doctors, patient advocacy organizations and community groups to increase awareness of industry patient assistance programs, and the Together Rx Access Card, which provides savings on more than 275 brand-name prescription medicines and products. [www.pparx.org](http://www.pparx.org), [www.togetherrxaccess.com](http://www.togetherrxaccess.com)

## Global AIDS Care

Abbott and the Abbott Fund are investing \$100 million to address HIV/AIDS in the developing world through programs that involve a comprehensive approach to fight stigma and discrimination, expand access to testing and treatment, prevent mother-to-child transmission of HIV, strengthen health care infrastructure, train health care workers and deliver services to orphans and vulnerable children impacted by HIV/AIDS. Working in partnership with governments, nongovernmental organizations, local communities and industry peers, these programs have helped hundreds of thousands of people over the past five years. [www.abbottglobalcare.org](http://www.abbottglobalcare.org)

## Product Donations

Abbott provides product donations to support medical missions and other global humanitarian efforts.

## Abbott's Commitment to Global Citizenship

### Corporate Governance

Abbott has a long tradition of ensuring the independence of the majority of our board of directors. All members of the public policy, audit, compensation, and nominations and governance committees are independent. Among the criteria for candidates of the board are a global business perspective and a commitment to good corporate citizenship. The charter of the public policy committee of the board includes the review and evaluation of Abbott's policies and procedures with respect to social responsibility.

### Ethics and Compliance

Ethical conduct and compliance with the law are central to fulfilling our responsibilities to our patients, customers and shareholders. Making ethical decisions and acting responsibly is the job of every Abbott employee. The Office of Ethics and Compliance reinforces our company's commitment to promote a culture of integrity and provides employees with a number of resources on ethics and compliance issues, including the Abbott Code of Business Conduct, an Ethics and Compliance Helpline, division-level compliance staff, and comprehensive in-person and Web-based training programs.

### Diversity and Inclusiveness

Discovering, developing and producing world-class pharmaceutical, nutritional and diagnostics products is a competitive arena where new ideas and approaches are critical. Our employee population reflects the people who use our products, and we work to create an environment that is inclusive and enables all people to contribute to their full potential. Diversity and inclusiveness are reflected in our company's policies and practices, including hiring and advancement, leadership development and work-life benefits.

### Environment, Health and Safety

We conduct our business in a manner designed to be protective of human health, safety and the environment. We strive to be a leader in health, safety and environmental performance, while developing new strategies, standards and systems for continuous improvement. We have long-established annual targets for measuring our environmental, health and safety performance that support our company's growth.

## Five-Year Financial Summary (a)

(dollars in millions, except per share data)

Year ended December 31	2005	2004	2003	2002	2001
Summary of Operations:					
Net Sales	\$ 22,337.8	19,680.0	17,280.3	15,279.5	13,918.5
Cost of products sold	\$ 10,641.1	8,884.2	7,774.2	6,820.5	6,107.1
Research and development (a)	\$ 1,821.2	1,696.8	1,623.8	1,474.5	1,491.8
Selling, general and administrative	\$ 5,496.1	4,921.8	4,808.1	3,724.9	3,491.0
Operating earnings	\$ 4,362.3	3,898.3	2,974.0	3,151.9	1,498.2
Interest expense	\$ 241.4	200.2	188.3	238.9	307.3
Interest income	\$ (87.7)	(51.1)	(41.9)	(33.5)	(71.4)
Other (income), net	\$ (411.3)	(376.4)	(559.5)	(374.4)	(231.3)
Earnings from continuing operations before taxes	\$ 4,619.9	4,125.6	3,387.2	3,321.0	1,493.6
Taxes on earnings from continuing operations	\$ 1,247.9	949.8	882.4	774.0	215.9
Earnings from continuing operations	\$ 3,372.1	3,175.8	2,504.7	2,547.0	1,277.7
Basic earnings per share from continuing operations	\$ 2.17	2.03	1.60	1.63	0.82
Diluted earnings per share from continuing operations	\$ 2.16	2.02	1.59	1.62	0.82
Financial Position:					
Working capital	\$ 3,970.5	3,908.8	2,650.9	2,119.6	492.4
Long-term investments	\$ 134.0	145.8	406.4	250.8	647.2
Net property and equipment	\$ 6,003.1	6,007.9	6,281.8	5,828.1	5,551.5
Total assets	\$ 29,141.2	28,767.5	26,039.3	23,592.7	22,755.5
Long-term debt	\$ 4,571.5	4,787.9	3,452.3	4,274.0	4,335.5
Shareholders' investment	\$ 14,415.3	14,325.8	13,072.3	10,664.6	9,059.4
Return on shareholders' investment from continuing operations	% 23.5	23.8	22.6	28.0	15.9
Book value per share	\$ 9.37	9.18	8.36	6.82	5.83
Other Statistics:					
Gross profit margin	% 52.4	54.9	55.0	55.4	56.1
Research and development to net sales	% 8.2	8.6	9.4	9.7	10.7
Net cash from operating activities of continuing operations	\$ 5,047.4	4,306.0	3,385.2	3,653.5	3,083.7
Capital expenditures	\$ 1,207.5	1,291.6	1,050.1	1,105.4	963.6
Cash dividends declared per common share	\$ 1.10	1.04	0.98	0.94	0.84
Common shares outstanding (in thousands)	1,539,235	1,560,024	1,564,518	1,563,068	1,554,530
Number of common shareholders	82,237	88,582	91,212	94,687	97,760
Number of employees	59,735	60,617	58,181	57,819	56,426
Sales per employee (in dollars)	\$ 373,948	324,662	297,010	264,265	246,668
Market price per share – high	\$ 50.00	47.63	47.15	58.00	57.17
Market price per share – low	\$ 37.50	38.26	33.75	29.80	42.00
Market price per share – close	\$ 39.43	46.65	46.60	40.00	55.75

(a) In 2005, 2004, 2003, 2002 and 2001, Abbott also recorded pretax charges of \$17, \$279, \$100, \$108 and \$1,330, respectively, for acquired in-process research and development related to business acquisitions.

## Plant Locations

The company's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400. The locations of the company's major plants as of May 1, 2006, are listed below.

Abbott Park, Illinois	Jayuya, Puerto Rico
Abingdon, England	Kanata, Canada
Alameda, California	Katsuyama, Japan
Altavista, Virginia	Ludwigshafen, Germany
Barceloneta, Puerto Rico	North Chicago, Illinois
Brockville, Canada	Queenborough, England
Campoverde, Italy	Redwood City, California
Casa Grande, Arizona	Rio de Janeiro, Brazil
Clonmel, Ireland	Santa Clara, California
Columbus, Ohio	Sligo, Ireland
Cootehill, Ireland	Sturgis, Michigan
Delkenheim, Germany	Temecula, California
Des Plaines, Illinois	Worcester, Massachusetts
Fairfield, California	Zwolle, the Netherlands
Irving, Texas	

## Directors

Roxanne S. Austin <i>Former President and Chief Operating Officer, DIRECTV, Inc. El Segundo, Calif.</i>	Boone Powell, Jr. <i>Retired Chairman, Baylor Health Care System Dallas, Tex.</i>
William M. Daley <i>Chairman of the Midwest, JP Morgan Chase &amp; Co. Chicago, Ill.</i>	W. Ann Reynolds, Ph.D. <i>Retired President, The University of Alabama at Birmingham Birmingham, Ala.</i>
W. James Farrell <i>Chairman and Former Chief Executive Officer, Illinois Tool Works, Inc. Glenview, Ill.</i>	Roy S. Roberts <i>Managing Director, Reliant Equity Investors Chicago, Ill.</i>
H. Laurance Fuller <i>Retired Co-Chairman of the Board, BP Amoco, p.l.c. London, United Kingdom</i>	William D. Smithburg <i>Retired Chairman, President and Chief Executive Officer, The Quaker Oats Co. Chicago, Ill.</i>
Richard A. Gonzalez <i>President and Chief Operating Officer, Abbott</i>	John R. Walter <i>Retired President and Chief Operating Officer, AT&amp;T Corp. Basking Ridge, N.J.; Former Chairman and Chief Executive Officer, R.R. Donnelley &amp; Sons Co. Chicago, Ill.</i>
Jack M. Greenberg <i>Retired Chairman and Chief Executive Officer, McDonald's Corp. Oak Brook, Ill.</i>	Miles D. White <i>Chairman of the Board and Chief Executive Officer, Abbott</i>
The Rt. Hon. Lord Owen CH <i>Chairman of Global Natural Energy, p.l.c. London, United Kingdom</i>	

## Senior Management

Miles D. White* <i>Chairman of the Board and Chief Executive Officer</i>	Jeffrey R. Binder* <i>Senior Vice President, Diagnostic Operations</i>	John C. Landgraf* <i>Senior Vice President, Global Pharmaceutical Manufacturing and Supply</i>
Richard A. Gonzalez* <i>President and Chief Operating Officer</i>	Olivier Bohuon* <i>Senior Vice President, International Operations</i>	Gary E. McCullough* <i>Senior Vice President, Ross Products</i>
Richard W. Ashley* <i>Executive Vice President, Corporate Development</i>	Thomas F. Chen* <i>Senior Vice President, Nutrition International Operations</i>	Laura J. Schumacher* <i>Senior Vice President, Secretary and General Counsel</i>
Thomas C. Freyman* <i>Executive Vice President, Finance and Chief Financial Officer</i>	William G. Dempsey* <i>Senior Vice President, Pharmaceutical Operations</i>	James L. Tyree* <i>Senior Vice President, Global Nutrition</i>
Holger Liepmann* <i>Executive Vice President, Pharmaceutical Products Group</i>	Edward J. Fiorentino* <i>Senior Vice President, Diabetes Care Operations</i>	
Joseph M. Nemmers, Jr.* <i>Executive Vice President, Diagnostic and Animal Health Divisions</i>	Stephen R. Fussell* <i>Senior Vice President, Human Resources</i>	

## Corporate Vice Presidents

Carlos Alban <i>Vice President, European Operations</i>	Robert E. Funck <i>Vice President and Treasurer</i>	Edward L. Michael <i>Vice President and President, Molecular Diagnostics</i>
Greg E. Arnsdorff <i>Vice President and President, Point of Care</i>	Robert B. Hance <i>Vice President and President, Vascular Devices</i>	Sean E. Murphy <i>Vice President, Global Licensing/New Business Development</i>
Alejandro A. Aruffo, Ph.D. <i>Vice President, Global Pharmaceutical Development and President, Abbott Bioresearch Center</i>	Lawrence E. Kraus <i>Vice President, Manufacturing, Global Pharmaceutical Operations</i>	Daniel W. Norbeck, Ph.D. <i>Vice President, Global Pharmaceutical Discovery</i>
Catherine V. Babington <i>Vice President, Public Affairs</i>	Zahir A. Lavji <i>Vice President, Japan Operations</i>	D. Stafford O'Kelly <i>Vice President, Latin America and Canada</i>
Michael G. Beatrice, Ph.D. <i>Vice President, Corporate Regulatory and Quality Science</i>	Elaine R. Leavenworth <i>Vice President, Government Affairs</i>	Donald V. Patton, Jr. <i>Vice President, Diagnostic Global Commercial Operations</i>
Charles M. Brock <i>Vice President, Chief Ethics and Compliance Officer</i>	John M. Leonard, M.D. <i>Vice President, Global Pharmaceutical Research and Development</i>	AJ J. Shoultz <i>Vice President, Taxes</i>
William E. Brown III, Ph.D. <i>Vice President, Diagnostic Assays and Systems Development</i>	Greg W. Linder* <i>Vice President and Controller</i>	Preston T. Simons <i>Vice President, Information Technology</i>
Douglas C. Bryant <i>Vice President, Molecular Global Commercial Operations</i>	Richard J. Marasco <i>Vice President, Nutrition International, Europe and Canada</i>	Eugene Sun, M.D. <i>Vice President, Global Pharmaceutical Clinical Development</i>
Michael J. Collins <i>Vice President, Medical Products Group Health Systems</i>	Heather L. Mason <i>Vice President, International Marketing</i>	Mary T. Szela <i>Vice President, Commercial Pharmaceutical Operations</i>
Jaime Contreras <i>Vice President, Diagnostic Commercial Operations, Europe, Africa and Middle East</i>	Mark Masterson <i>Vice President, Pacific, Asia and Africa Operations</i>	John B. Thomas <i>Vice President, Investor Relations</i>
	P. Loreen Mersheimer <i>Vice President, Integrated Healthcare Marketing and Policy</i>	Susan M. Widner <i>Vice President, Corporate Marketing</i>

Thomas J. Dee  
*Vice President, Internal Audit*

\*Denotes executive officers



Published by Abbott's Investor Relations/Public Affairs Division.  
Corporate Public Affairs: (847) 937-1608; Investor Newline: (847) 937-7300

The ticker symbol for Abbott's common stock is ABT. It is listed on the New York, Chicago, Pacific, London and Swiss exchanges. It is traded on the Boston, Cincinnati and Philadelphia exchanges.

On the cover: Yew Han Yong is an active 3-year-old from Singapore who enjoys preschool. He maintains his energy, thanks in part to *Grow*, a nutritional supplement for children that delivers important nutrients to enhance their daily diet.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Not all products listed are approved in all countries.

©2006, Abbott 120M/5/06

Abbott  
100 Abbott Park Road  
Abbott Park, IL 60064-6400 U.S.A.  
(847) 937-6100 [www.abbott.com](http://www.abbott.com)

